Matinas BioPharma Holdings (MTNB) Other financing activities (2013 - 2025)
Matinas BioPharma Holdings (MTNB) reported Other financing activities of $27000.0 for Q2 2025, up 1250.0% quarter-over-quarter from $2000.0 in Q1 2025.
Matinas BioPharma Holdings (MTNB) Other financing activities (2013 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 3 years of Other financing activities data on file, last reported at $27000.0 in Q2 2025.
- Other financing activities for Q2 2025 came in at $27000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $29000.0 (changed N/A YoY), and the FY2025 annual result was $29000.0, changed N/A from the prior year.
- Other financing activities rose to $27000.0 in Q2 2025 per MTNB's latest filing, from $2000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $27000.0 in Q2 2025 and troughed at $2000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2015 | -285.00 |
| Dec 31, 2015 | -285.00 |
| Sep 30, 2015 | 7,945.00 |
| Sep 30, 2015 | 7,945.00 |
| Jun 30, 2015 | 823,070.00 |
| Jun 30, 2015 | 823,070.00 |
| Mar 31, 2015 | 654,766.00 |
| Mar 31, 2015 | 654,766.00 |
| Dec 31, 2013 | 2.38 Mn |
| Dec 31, 2013 | 2.38 Mn |